The pivotal Pfizer COVID-19 vaccine trial never proved benefits outweighed risks, according to a new analysis by researcher Yaakov Ophir.
The widely publicized 95% efficacy figure was based on a narrow, short-term measure that did not account for transmission or asymptomatic spread.
Serious adverse events were numerically higher in the vaccine group, while the gap in severe COVID cases between groups was statistically insignificant.
Regulators never performed a side-by-side risk-benefit comparison, leaving the full picture of potential harms undisclosed before mandates were imposed.
Ophir argues this evidence must be revisited now to ensure the same mistakes are not repeated during the next public health emergency.
Five years after the Pfizer-BioNTech COVID-19 vaccine was rushed onto the market under emergency authorization, a new analysis by researcher Yaakov Ophir, Ph.D., has concluded that the pivotal clinical trial never demonstrated the vaccine’s benefits outweighed its risks. The finding arrives as Health and Human Services Secretary Robert F. Kennedy Jr. moves to terminate the emergency use declarations that governed the vaccine’s rollout. Ophir’s analysis, published by the Brownstone Institute, examined the same evidence the U.S. Food and Drug Administration reviewed in December 2020 and found a far less favorable picture than the widely publicized 95% efficacy figure suggested.
Read Full Article: https://www.naturalnews.com/2026-07-28-pfizer-trial-data-harm-researcher.html
